Nanoform granted funding to tackle global health challenges

pharmafile | September 30, 2021 | News story | Business Services  

Innovative nanoparticle medicine company, Nanoform, has announced that proof of concept studies will receive funding from the Bill & Melinda Gates Foundation. The aim of this funding is to assess the added value that Nanoform’s CESS® nanoparticle engineering technology can deliver to its drug development projects.

Nanoform is developing nanomedicines with an end goal of solving significant world health issues, through providing and commercialising more life-changing drug candidates. The company works together with pharma and biotech partners globally, to enhance patient care by developing medicines that use Nanoform’s platform technologies.

Christian Jones, CCO of Nanoform, commented: “Our goal is to improve the lives of over 1 billion patients. We are delighted to receive this funding from the Gates Foundation to evaluate how our proprietary CESS platform can help more novel therapies reach patients who need them.

“Too many medicines suffer from poor solubility and bioavailability and never make it to market, not to mention the challenge many patients have in accessing medicines globally. By applying Nanoform’s innovative technologies and multidisciplinary expertise we strive to unlock many new therapies for patients going forward.”  

Nanoform’s capabilities include GMP manufacturing, and its services span the small to large molecule development space, with a focus on tackling challenges in drug solubility and bioavailability, and on enabling new drug delivery applications. Their portfolio has included major US pharma clients, including AstraZeneca in 2019, to boost the value of Nanoform’s proprietary products.

Lina Adams

Related Content

No items found

Latest content